Clinical trial · Observational
SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access
Screening Platform of EORTC for Clinical Trials Access in Brain Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study has been merged with 1553 SPECTA, in which brain patients are enrolled
Summary
Brief summary (as posted)
The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to: * Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor; * Identify or validate new molecularly defined subgroups of tumors; * Investigate the prevalence of novel biomarkers to plan future clinical trials; * Enable exploratory/future research; * Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tumour markers testing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Brain cancer
- description
- Patients with diagnosis of brain cancer at any stage
- interventionNames
- Genetic: Tumour markers testing
Primary outcomes (1)
- measure
- Number of patients with brain malignancy
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed newly diagnosed primary CNS tumors, with a focus on diffuse gliomas of grades II, III and IV, meningiomas from patients who are candidates for pharmacotherapy, and rare CNS tumors; * Availability of adequate Human Biological Material (HBM): FFPE tissue sample from the primary and/or recurrent tumor and/or metastasis, obtained at the time of surgery or biopsy; minimal amount requested is detailed in the HBM guidelines. Inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional; * At least three months life expectancy; * Written informed consent according to ICH/GCP and national/local regulations; * Absence of exclusion criteria, such as active hepatitis B/C or HIV, second malignancies, severe organ dysfunction, or other comorbidities that will prevent inclusion into clinical trials.
References
Publications (0)
Data not yet available